A41 A40
Conditions
Interventions
Group 1: Patients with Sepsis:
Blood sampling at four time points
- onset
- 72h
- 168h
- 14-42days (depending on disease progression)
Group 2: Healthy probands:
single blood sampling
Sponsors
Klinik für Anästhesiologie - Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with Sepsis: Consent by the legal representative At least 2 SIRS criteria met: - temperature 38ºC - tachycardia (> 90 /min) - leukocytosis (> 12,000 /µl) OR leukopenia (10% immature blasts) - Tachypnea (> 20 /min) OR paCO2 <32 mmHg OR oxygenation index (FiO2/paO2) <200 OR mechanical Ventilation Clinical or microbiological evidence of infection Sepsis-associated organ dysfunction indicated by a change in the Sequential Organ Failure Assessment (SOFA) score by 2 or more points (compared to previous day) Healthy volunteers: Informed consent
Exclusion criteria
Exclusion criteria: Common exclusion criteria of all study groups: Pregnancy Inclusion in an interventional study Infectious viral diseases (HBV, HCV, HIV) Iatrogenic immunosuppression Pre-existing autoimmune diseases Treatment with checkpoint inhibitors Specific exclusion criteria of patients with sepsis: Diagnosis "sepsis" >24 h. Specific exclusion criteria of healthy volunteers: One of the following states during the last 7 days: - Influenza infection or flu - Sports injuries or other trauma - Large-scale dental interventions (e.g., tooth extraction) - Blood or platelet donation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunophenotyping of immune cell populations by flow cytometric analysis of immune receptors on the cell surface of monocytes, granulocytes, low-density granulocytes and MDSC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurment of the influence of the immune cell populations with immunosuppressor function on T-cell proliferation using stimulation and flow cytometry Measurment of functional competence of the individual subpopulations for cytokine release using stimulation and ELISA Quantification of chemokines, cytokines, metabolites and enzyme activities in plasma and in isolated immune cell populations using ELISA and mass spectrometry Measurement of the metabolic pathways used in isolated immune cell populations using Seahorse™ technology Measurement of gene expression, in particular with regard to changes in factors relevant for immunosuppressive functions using qPCR Occurrence of secondary infections 28-day survival Length of stay in hospital and intensive care unit | — |
Countries
Germany
Contacts
Public ContactMarkus A. Weigand
Klinik für Anästhesiologie - Universitätsklinikum Heidelberg
Outcome results
None listed